Drugs Containing Excipient (Inactive Ingredient) POLYETHYLENE OXIDE 900000

« Back to Dashboard

Generic drugs containing POLYETHYLENE OXIDE 900000 excipient

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	buprenorphine and naloxone	0378-8765	POLYETHYLENE OXIDE 900000
Mylan Pharmaceuticals Inc	buprenorphine and naloxone	0378-8767	POLYETHYLENE OXIDE 900000
Aveva Drug Delivery Systems Inc	buprenorphine and naloxone	3215-6521	POLYETHYLENE OXIDE 900000
Alvogen Inc	buprenorphine and naloxone	47781-355	POLYETHYLENE OXIDE 900000
A-S Medication Solutions	desvenlafaxine	50090-4388	POLYETHYLENE OXIDE 900000

Polyethylene Oxide 900,000 Excipient Market Dynamics and Financial Trajectory

Last updated: October 9, 2026

Polyethylene oxide with an average molecular weight near 900,000 is a high-molecular-weight, water-soluble excipient used primarily as a tablet binder, matrix former, viscosity modifier, mucoadhesive, and controlled-release polymer. The grade is commonly associated with Dow’s POLYOX WSR 1105 family, although commercial specifications and molecular-weight designations vary by supplier.

Demand is driven by extended-release oral solids, abuse-deterrent formulations, gastroretentive systems, and pharmaceutical manufacturing processes that require reproducible hydration and gel formation. The market is technically defensible but fragmented. Public companies generally do not disclose revenue for individual polyethylene oxide grades, so the financial trajectory must be assessed through formulation demand, capacity, pricing, regulatory qualification, and supplier concentration rather than product-level sales.

What is polyethylene oxide 900,000 used for in pharmaceuticals?

Polyethylene oxide 900,000, often abbreviated PEO 900K, is a nonionic, water-soluble polymer. Its pharmaceutical value comes from its ability to hydrate, increase viscosity, bind powders, and form a gel barrier that slows drug diffusion and tablet erosion.

Attribute	Typical description
Material	Polyethylene oxide
Approximate molecular weight	900,000
Common function	Controlled-release matrix former, binder, viscosity modifier, mucoadhesive
Physical form	White or off-white free-flowing powder
Solubility	Water-soluble; hydration rate depends on grade and processing
Main dosage form	Oral tablets
Secondary applications	Films, gels, ophthalmic and mucosal systems, abuse-deterrent formulations
Key quality variables	Molecular-weight distribution, hydration rate, viscosity, moisture, particle size, residual impurities
Principal commercial risk	Supplier qualification and grade substitution

PEO 900K is distinct from polyethylene glycol, or PEG. PEG generally refers to lower-molecular-weight grades used as solvents, plasticizers, humectants, and ointment bases. PEO 900K has a much higher molecular weight and is selected for viscosity, gel strength, and release-control performance.

What pharmaceutical formulations are protected by polyethylene oxide 900,000?

PEO 900K is most valuable in matrix tablets. The polymer hydrates after administration and creates a gel layer around the tablet. The resulting barrier controls penetration of gastrointestinal fluids and release of the active ingredient.

Controlled-release tablets

The principal formulation use is hydrophilic matrix technology. PEO 900K can be used alone or combined with lower-molecular-weight PEO, hydroxypropyl methylcellulose, hydroxypropyl cellulose, carbomers, or other release-controlling polymers.

Formulation performance depends on:

• Polymer concentration.
• Tablet compression force.
• Drug solubility and dose.
• Tablet geometry.
• Agitation and gastrointestinal conditions.
• Polymer hydration and erosion rates.
• Particle size and blending sequence.

High-molecular-weight PEO is often used where a stronger gel and slower erosion profile are required. It can reduce the need for high polymer loading compared with lower-viscosity grades, although the final choice depends on active pharmaceutical ingredient properties.

Abuse-deterrent formulations

PEO is used in some abuse-deterrent oral dosage technologies because hydration can produce a viscous or gel-like mass that complicates crushing, extraction, syringeability, or rapid administration. FDA guidance treats abuse deterrence as a product-specific performance claim rather than an automatic property of the excipient.[1]

The polymer alone does not establish an abuse-deterrent claim. Sponsors must demonstrate performance against the relevant manipulation methods and support labeling through FDA review.

Mucoadhesive and mucosal systems

PEO 900K can increase residence time on mucosal tissue and support local delivery. Potential applications include buccal, sublingual, nasal, vaginal, and gastrointestinal systems. These uses remain more formulation-specific than conventional matrix-tablet applications.

What is the FDA regulatory status of polyethylene oxide 900,000?

PEO 900K is an excipient, not an independently approved drug. FDA evaluates its use through the finished dosage form, manufacturing process, safety package, and proposed route of administration.

FDA Inactive Ingredient Database

The FDA Inactive Ingredient Database is the primary public reference for prior use of excipients in approved drug products. A listing can support regulatory justification, but it does not create a blanket approval for every molecular weight, concentration, route, or dosage form.[2]

For PEO 900K, the relevant assessment must distinguish:

1. Exact polymer identity.
2. Molecular-weight range.
3. Route of administration.
4. Maximum precedent concentration.
5. Dosage form.
6. Grade-specific quality attributes.

A sponsor using a higher concentration, new route, or materially different grade may need additional toxicology, extractables, impurity, and clinical justification.

Compendial and quality considerations

Pharmaceutical-grade PEO is generally controlled through supplier specifications, applicable pharmacopeial standards, and product-specific controls. Critical release tests include viscosity, molecular-weight distribution, loss on drying or water content, residue on ignition, microbial quality, and identity.

A material may meet a compendial identity standard while still being unsuitable as a direct substitute for a qualified commercial grade. Hydration rate, shear sensitivity, particle morphology, and molecular-weight distribution can change dissolution performance without changing the nominal chemical identity.

Which companies supply polyethylene oxide 900,000?

Dow is the best-known global supplier through the POLYOX water-soluble resin platform. Other suppliers participate in the broader PEO and high-molecular-weight water-soluble polymer market, although exact pharmaceutical-grade equivalence must be confirmed grade by grade.

Supplier or supplier group	Relevant position	Commercial implication
Dow	POLYOX water-soluble resins, including high-molecular-weight pharmaceutical grades	Strong reference status and broad regulatory history
Nippon Shokubai	Polyethylene oxide and specialty polymer capabilities	Potential regional and technical alternative
Sumitomo Seika Chemicals	Water-soluble polymers and specialty absorbent materials	Relevant manufacturing and polymer expertise
Regional specialty-polymer producers	Custom or alternative PEO grades	Lower-cost or geographic diversification options
Contract compounders and distributors	Local supply and technical support	Useful for qualification and inventory continuity

Supplier competition is constrained by qualification costs. A formulation sponsor typically cannot switch from one PEO 900K supplier to another without comparative dissolution, compression, stability, and process studies.

How strong is the intellectual-property position for polyethylene oxide 900,000?

The polymer itself is generally a mature, off-patent chemical substance. The stronger IP positions usually relate to formulations, manufacturing methods, dosage forms, and therapeutic applications.

Formulation patents

Potentially relevant claims include:

• A specific PEO molecular-weight range.
• Defined polymer ratios.
• Drug-to-polymer loading.
• Tablet hardness and geometry.
• Controlled-release dissolution profiles.
• Abuse-deterrent processing.
• Combination of PEO with another hydrophilic polymer.
• Coating or multilayer tablet architecture.

A formulation patent may cover the use of PEO 900K even when the raw material is broadly available. Freedom-to-operate analysis must therefore focus on the finished product and not only on the excipient.

Manufacturing and process IP

Manufacturing barriers can include:

• Polymerization control.
• Molecular-weight distribution.
• Residual monomer limits.
• Drying and milling.
• Powder handling.
• Packaging against moisture uptake.
• Batch-to-batch viscosity control.

These processes may be protected by patents, trade secrets, or accumulated know-how. For mature PEO grades, manufacturing consistency and regulatory history are often more important commercial barriers than basic composition patents.

How does polyethylene oxide 900,000 compare with other release-control excipients?

Excipient	Principal strength	Limitation versus PEO 900K
PEO 900K	Strong hydration, high viscosity, matrix formation	Sensitive to processing and molecular-weight variation
HPMC	Broad regulatory history and established matrix technology	May require higher loading for some release profiles
HPC	Good film and matrix properties	Different hydration and gel behavior
Carbomer	High viscosity at low concentration	pH sensitivity and processing constraints
Sodium alginate	Ionic gel formation and mucoadhesion	Greater sensitivity to ions and formulation environment
Ethylcellulose	Insoluble diffusion barrier	Requires coating or specialized matrix design
Polyvinyl acetate-based systems	Robust extended release	Less water-soluble and more formulation-specific

PEO 900K is most competitive where the sponsor needs a strong hydrophilic gel, high viscosity, or a combination of release control and mechanical resistance. HPMC remains the benchmark in many oral controlled-release products because of its extensive regulatory and formulation history.

What market dynamics are shaping PEO 900K demand?

Growth drivers

Demand should remain linked to several pharmaceutical trends:

• Increased use of once-daily oral products.
• Lifecycle management through extended-release reformulation.
• Expansion of generic controlled-release products.
• Continued development of abuse-deterrent dosage forms.
• Growth in high-dose oral drugs requiring matrix technologies.
• Greater use of platform excipients across multiple products.
• Demand for lower-complexity manufacturing compared with osmotic or multiparticulate systems.

PEO 900K can be attractive in generic development because it enables a familiar hydrophilic-matrix approach without requiring complex delivery equipment.

Demand constraints

The material faces structural limitations:

• High-molecular-weight PEO can be difficult to blend and compress.
• Over-lubrication or excessive shear can change tablet performance.
• Molecular-weight degradation can affect release rates.
• Substitution can trigger substantial comparability work.
• Large-volume buyers may negotiate aggressively.
• HPMC and other cellulose polymers remain entrenched in development programs.
• A single polymer grade may not fit all active ingredients.

The result is a specialized excipient market with recurring demand but limited volume growth from any single product.

What is the financial trajectory for polyethylene oxide 900,000?

Public financial data for PEO 900K as an individual excipient grade is not generally disclosed. The financial trajectory is therefore best described as stable-to-growing, with margin protection dependent on qualification status and supply reliability rather than on raw-material volume alone.

Revenue profile

PEO 900K revenue is generated through:

1. New drug-development projects.
2. Commercial supply to approved products.
3. Generic formulation programs.
4. Reformulation and lifecycle-management projects.
5. Distributor and regional inventory channels.

Commercial products create the highest-quality demand because an approved formulation can continue purchasing the qualified grade for many years. Development-stage demand is less predictable and can disappear when a program fails, changes dosage form, or selects another polymer.

Margin dynamics

Margins are supported by:

• Technical qualification.
• Regulatory documentation.
• High switching costs.
• Limited validated alternatives.
• Customer dependence on consistent viscosity and dissolution behavior.

Margins are pressured by:

• Raw-material and energy costs.
• Capacity additions.
• Generic-drug price competition.
• Large customer purchasing power.
• Distributor markups and inventory costs.
• Qualification of lower-cost Asian suppliers.

The economic value of a pharmaceutical PEO grade is therefore higher than the value implied by its chemical commodity status. Suppliers with strong documentation, global manufacturing, and change-control systems can command a premium.

Scenario outlook

Scenario	Market effect	Financial result
Base case	Steady controlled-release and generic demand	Low- to mid-single-digit revenue growth potential for the niche
Upside case	More abuse-deterrent products and broad generic adoption	Higher volume and stronger utilization of qualified capacity
Downside case	Substitution by HPMC, supply interruptions, or customer consolidation	Flat volume and pricing pressure
Severe downside	Major quality event or regulatory concern involving a reference grade	Rapid customer requalification and temporary demand loss

These are directional industry scenarios, not audited forecasts for a specific supplier.

What generic entry risks exist for products using PEO 900K?

PEO 900K can create formulation-development risk for generic applicants even when the active ingredient’s primary patent has expired. Controlled-release products often require bioequivalence under complex dissolution and pharmacokinetic conditions.

Generic sponsors may need to match:

• Polymer grade and molecular-weight range.
• Polymer loading.
• Tablet compression conditions.
• Dissolution across multiple media and agitation speeds.
• Food-effect performance.
• Alcohol-induced dose dumping behavior.
• Stability after scale-up.

A supplier change can create a regulatory filing burden if the new grade alters release behavior. This gives qualified suppliers a degree of commercial protection after product launch.

What patent and litigation issues affect PEO 900K?

PEO 900K itself is unlikely to create a major standalone patent cliff comparable to an active pharmaceutical ingredient. Litigation exposure usually sits in the finished product’s controlled-release or abuse-deterrent patent estate.

Relevant disputes can involve:

• Markush claims covering hydrophilic polymers.
• Narrow molecular-weight claims.
• Dissolution-profile claims.
• Manufacturing-process claims.
• Method-of-use claims.
• Patent-certification disputes involving abbreviated new drug applications.

Because PEO 900K is a formulation component, it may be present in products protected by Orange Book-listed patents. The excipient is not itself an Orange Book-listed drug product, and there is no standalone Paragraph IV pathway directed to PEO 900K. Paragraph IV risk arises when a generic applicant challenges patents listed for a finished drug that uses PEO or a similar matrix system.[3]

What geographic coverage and supply-chain risks exist?

North America, Europe, Japan, China, India, and South Korea are the main relevant manufacturing and consumption regions. Global customers generally prefer suppliers capable of supporting multiple regulatory jurisdictions with consistent documentation.

Key supply-chain risks include:

• Concentration among a small number of validated manufacturers.
• Long change-control cycles.
• Regional transport and inventory disruptions.
• Moisture-sensitive packaging requirements.
• Limited immediate substitutes.
• Divergent pharmacopeial and regulatory expectations.
• Capacity allocation during generic launches.

Dual sourcing is difficult but commercially valuable. A second source must demonstrate equivalent performance, not merely the same nominal molecular weight.

Key Takeaways

• Polyethylene oxide 900,000 is a high-value functional excipient used mainly in controlled-release matrix tablets.
• Dow’s POLYOX platform is the principal reference point, although alternative suppliers exist.
• The polymer is chemically mature, but formulation, process, and manufacturing know-how can remain commercially defensible.
• FDA status depends on route, concentration, dosage form, and grade-specific precedent in the Inactive Ingredient Database.
• Revenue data for the individual grade is not publicly reported; financial value is assessed through recurring commercial products and qualification barriers.
• Demand should remain stable to moderately growing, supported by extended-release generics and lifecycle-management programs.
• The principal risks are substitution by HPMC, supplier concentration, grade variability, and customer price pressure.
• Patent risk generally attaches to the finished dosage form rather than to PEO 900K itself.
• Generic applicants face meaningful comparability work when changing polymer grade or release-control architecture.

FAQs

Is polyethylene oxide 900,000 the same as PEG 900,000?

No. PEO 900K is a high-molecular-weight water-soluble polymer used for viscosity and controlled release. PEG normally refers to lower-molecular-weight polyethylene glycol materials used as solvents, plasticizers, humectants, or bases.

Can HPMC replace PEO 900K in a controlled-release tablet?

Potentially, but substitution requires formulation redevelopment. Differences in hydration, gel strength, erosion, compression behavior, and dissolution can prevent a direct one-for-one replacement.

Does PEO 900K have an FDA approval number?

No standalone FDA approval number applies to the excipient. FDA evaluates the material as part of a finished pharmaceutical product and through prior-use information such as the Inactive Ingredient Database.

Is PEO 900K protected by an active composition patent?

The base polymer is a mature chemical material. Active intellectual-property exposure is more likely to involve specific formulations, molecular-weight ranges, processing methods, release profiles, or abuse-deterrent dosage forms.

What is the main investment risk in the PEO 900K market?

The main risk is limited transparency combined with supplier concentration. Individual-grade revenue is rarely disclosed, while customer qualification and regulatory requirements can make supply interruptions or quality events commercially significant.

References

1. U.S. Food and Drug Administration. (2020). General principles for evaluating the abuse deterrence of generic solid oral opioid drug products. FDA.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. Dow Chemical Company. (n.d.). POLYOX water-soluble resins: Pharmaceutical applications and product information. Dow.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.